Previous 10 | Next 10 |
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive...
Forty Seven (NASDAQ: FTSV), a clinical stage immuno-oncology company, has closed an underwritten public offering of 10,781,250 shares of its common stock, which includes 1,406,250 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the...
MENLO PARK, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 10,781,250 shares of common stock, including 1,406,250 shares sold pursuant to the und...
Forty Seven (NASDAQ: FTSV ) has priced its public offerin g of 9.375M common shares at $8 per share. Underwriters over-allotment is an additional ~1.406M shares. Closing date is July 22. More news on: Forty Seven, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MENLO PARK, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a price to the public of $8.00 pe...
Gainers: ORN +31.7% . SGEN +8.2% . CTAS +6.2% . IMMR +5.5% . ELP +3.4% . More news on: Orion Group Holdings, Inc., Seattle Genetics, Inc., Cintas Corporation, Stocks on the move, Read more ...
MENLO PARK, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being o...
-- Ono to Receive Exclusive License for All Therapeutic Uses of 5F9 in Select Asian Markets -- -- Forty Seven to Receive up to $120M in Combined Upfront and Potential Development and Commercial Milestone Payments, in Addition to Royalties on Net Sales -- MENLO PARK, Calif., July 11, 2...
-- 5F9 Well-Tolerated in Combination with Rituximab -- -- Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached -- -- Overall Response Rate (ORR) of 36% Observed in DLBCL and ORR of 61% Observed in Indolent Lymphoma -- -- FDA Feedback ...
The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...